Hs. Debinski et Ma. Kamm, NOVEL DRUG THERAPIES IN INFLAMMATORY BOWEL-DISEASE, European journal of gastroenterology & hepatology, 7(2), 1995, pp. 169-182
This paper reviews the published data on novel drug treatments for inf
lammatory bowel disease. Steroids that are topically active or rapidly
metabolized have a definite therapeutic role and have fewer long-term
side-effects than other steroids. Methotrexate can promote remission
in approximately 50% of patients, but is less effective in maintaining
remission. Cyclosporin is valuable for treating patients with severe
ulcerative colitis but is less valuable for patients with Crohn's dise
ase. None of the drugs that modify specific inflammatory mediators hav
e proven efficacy but tumour necrosing factor and CD4 antibodies may b
e promising. In patients with distal colitis, lignocaine appears to be
effective